Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST)

BACKGROUND: Patients with advanced gastrointestinal stromal tumours (GISTs) resistant to the tyrosine kinase inhibitors imatinib and sunitinib may be treated with regorafenib, which resulted in a median progression-free survival (PFS) of 4.8 months in the GRID trial. Also, pazopanib, another tyrosin...

Descripción completa

Detalles Bibliográficos
Autores principales: Eriksson, M., Reichardt, P., Joensuu, H., Krarup-Hansen, A., Hagberg, O., Hohenberger, P., Hagberg, H., Hansson, L., Foukakis, T., Pulkkanen, K., Bauer, S., Goplen, D., Blach Rossen, P., Sundby Hall, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287147/
https://www.ncbi.nlm.nih.gov/pubmed/34271307
http://dx.doi.org/10.1016/j.esmoop.2021.100217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287147/
https://www.ncbi.nlm.nih.gov/pubmed/34271307
http://dx.doi.org/10.1016/j.esmoop.2021.100217

Ejemplares similares